For the subset of women with BRCA mutations who have already had ovarian cancer, risk-reducing mastectomy might not be worth the price tag. New research finds that for many women in this unique group, prophylactic mastectomy does not produce a substantial survival gain compared to breast cancer screening and is not cost-effective.